Color Online: See the article online to view Figures in colour.
Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients†
Version of Record online: 29 NOV 2010
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PROTEOMICS - Clinical Applications
Special Issue: Focus on Pathways to Translation of Proteomics into Clinical Practice
Volume 4, Issue 12, pages 940–952, December 2010
How to Cite
Høgdall, E., Fung, E. T., Christensen, I. J., Yip, C., Nedergaard, L., Engelholm, S. A., Risum, S., Petri, A. L., Lundvall, L., Lomas, L. and Høgdall, C. (2010), Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Prot. Clin. Appl., 4: 940–952. doi: 10.1002/prca.200900171
- Issue online: 29 NOV 2010
- Version of Record online: 29 NOV 2010
- Accepted manuscript online: 5 OCT 2010 09:00AM EST
- Manuscript Accepted: 23 AUG 2010
- Manuscript Revised: 4 AUG 2010
- Manuscript Received: 18 AUG 2009
- Ovarian cancer;
Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients.
Experimental design: Serum from 150 OC patients was tested using SELDI-TOF-MS.
Results: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65–3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17–2.70 together with type of surgery, age and chemotherapy.
Conclusions and clinical relevance: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.